Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Neurology and Neuroscience Reports
Erschienen in: Current Neurology and Neuroscience Reports 5/2011

01.10.2011

Cognitive Impairment in Huntington Disease: Diagnosis and Treatment

verfasst von: Jane S. Paulsen

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Cognition has been well characterized in the various stages of Huntington disease (HD) as well as in the prodrome before the motor diagnosis is given. Although the clinical diagnosis of HD relies on the manifestation of motor abnormalities, the associated impairments have been growing in prominence for several reasons. First, research to understand the most debilitating aspects of HD has suggested that cognitive and behavioral changes place the greatest burden on families, are most highly associated with functional decline, and can be predictive of institutionalization. Second, cognitive impairments are evident at least 15 years prior to the time at which motor diagnosis is given. Finally, cognitive decline is associated with biological markers such as brain atrophy, circulating levels of brain-derived neurotrophic factors, and insulin-like growth factor 1. Efforts are now underway to develop valid and reliable measures of cognition in the prodrome as well as in all stages of HD so that clinical trials can be conducted using cognitive outcomes.
Literatur
1.
The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72(6):971–83.CrossRef
2.
Ferrante RJ, Kowall NW, Beal MF, et al. Selective sparing of a class of striatal neurons in Huntington’s disease. Science. 1985;230(4725):561–3.PubMedCrossRef
3.
Hedreen JC, Peyser CE, Folstein SE, Ross CA. Neuronal loss in layers V and VI of cerebral cortex in Huntington’s disease. Neurosci Lett. 1991;133(2):257–61.PubMedCrossRef
4.
Aylward EH, Nopoulos PC, Ross CA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry. 2011;82:405–10.PubMedCrossRef
5.
Rosas HD, Hevelone ND, Zaleta AK, et al. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology. 2005;65(5):745–7.PubMedCrossRef
6.
Paulsen JS, Magnotta VA, Mikos AE, et al. Brain structure in preclinical Huntington’s disease. Biol Psychiatry. 2006;59(1):57–63.PubMedCrossRef
7.
8.
Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83–98.PubMedCrossRef
9.
Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol. 2006;63(6):883–90.PubMedCrossRef
10.
Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79(8):874–80.PubMedCrossRef
11.
Nance MA, Paulsen JS, Rosenblatt A, Wheelock V. A physician’s guide to the management of Huntington's disease. 3rd ed. Huntington's Disease Society of America 2011.
12.
Paulsen JS, Zhao H, Stout JC, et al. Clinical markers of early disease in persons near onset of Huntington’s disease. Neurology. 2001;57(4):658–62.PubMed
13.
Langbehn DR, Paulsen JS. Predictors of diagnosis in Huntington disease. Neurology. 2007;68(20):1710–7.PubMedCrossRef
14.
Biglan KM, Ross CA, Langbehn DR, et al. Motor abnormalities in premanifest persons with Huntington’s disease: the PREDICT-HD study. Mov Disord. 2009;24(12):1763–72.PubMedCrossRef
15.
Paulsen JS, Nopoulos PC, Aylward E, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2010;82(3–4):201–7.PubMedCrossRef
16.
Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology. 2004;63(1):66–72.PubMed
17.
Unified Huntington’s disease rating scale: reliability and consistency. Huntington Study Group. Mov Disord. 1996;11(2):136–142.
18.
Carlozzi NE, Stout JC, Mills JA, et al. Estimating premorbid IQ in the prodromal phase of a neurodegenerative disease. Clin Neuropsychol. 2011;25(5):757–77.
19.
O’Rourke JJ, Adams WH, Duff K, et al. Estimating premorbid functioning in huntington’s disease: the relationship between disease progression and the wide range achievement test reading subtest. Arch Clin Neuropsychol. 2011;26(1):59–66.PubMedCrossRef
20.
Petersen RC. Conversion. Neurology. 2006;67(9 Suppl 3):S12–13.PubMed
21.
Duff K, Beglinger LJ, Theriault D, et al. Cognitive deficits in Huntington’s disease on the Repeatable Battery for the Assessment of Neuropsychological Status. J Clin Exp Neuropsychol. 2009;1–9.
22.
23.
•• Peavy GM, Jacobson MW, Goldstein JL, et al. Cognitive and functional decline in Huntington’s disease: Dementia criteria revisited. Move Disord. 2010;25(9):1163–1169. This is the first paper to explicitly criticize current dementia criteria and propose appropriate criteria specific to HD. CrossRef
24.
Mickes L, Jacobson M, Peavy G, et al. A comparison of two brief screening measures of cognitive impairment in Huntington’s disease. Mov Disord. 2010;25(13):2229–33.PubMedCrossRef
25.
Hamilton JM, Salmon DP, Corey-Bloom J, et al. Behavioural abnormalities contribute to functional decline in Huntington’s disease. J Neurol Neurosurg Psychiatry. 2003;74(1):120–2.PubMedCrossRef
26.
Nehl C, Paulsen JS. Huntington Study Group: cognitive and psychiatric aspects of Huntington disease contribute to functional capacity. J Nerv Ment Dis. 2004;192(1):72–4.PubMedCrossRef
27.
Williams JK, Barnette JJ, Reed D, et al. Development of the Huntington disease family concerns and strategies survey from focus group data. J Nurs Meas. 2010;18(2):83–99.PubMedCrossRef
28.
Paulsen JS, Zimbelman JL, Hinton SC, et al. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington’s Disease. AJNR Am J Neuroradiol. 2004;25(10):1715–21.PubMed
29.
Nopoulos PC, Aylward EH, Ross CA, et al. Smaller intracranial volume in prodromal Huntington’s disease: evidence for abnormal neurodevelopment. Brain. 2011;134(Pt 1):137–42.PubMedCrossRef
30.
Lemay M, Fimbel E, Beuter A, et al. Sensorimotor mapping affects movement correction deficits in early Huntington’s disease. Exp Brain Res. 2005;165(4):454–60.PubMedCrossRef
31.
•• Say MJ, Jones R, Scahill RI, et al. Visuomotor integration deficits precede clinical onset in Huntington’s disease. Neuropsychologia 2011;49(2):264–270. This discusses a new task with potential for usage in clinical trials for HD. PubMedCrossRef
32.
•• Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011;10(1):31–42. This is one of few papers showing longitudinal data useful for clinical trial design. PubMedCrossRef
33.
Solomon AC, Stout JC, Weaver M, et al. Ten-year rate of longitudinal change in neurocognitive and motor function in prediagnosis Huntington disease. Mov Disord. 2008;23(13):1830–6.PubMedCrossRef
34.
Rupp J, Blekher T, Jackson J, et al. Progression in Prediagnostic Huntington Disease. J Neurol Neurosurg Psychiatry. 2010;81(4):379–84.
35.
Paulsen J. Early detection of Huntington’s disease. Future Neurology. 2010;5(1):85–104.CrossRef
36.
Hinton SC, Paulsen JS, Hoffmann RG, et al. Motor timing variability increases in preclinical Huntington’s disease patients as estimated onset of motor symptoms approaches. J Int Neuropsychol Soc. 2007;13(3):539–43.PubMedCrossRef
37.
Zimbelman JL, Paulsen JS, Mikos A, et al. fMRI detection of early neural dysfunction in preclinical Huntington’s disease. J Int Neuropsychol Soc. 2007;13(5):758–69.PubMedCrossRef
38.
•• Rowe KC, Paulsen JS, Langbehn DR, et al. Self-paced timing detects and tracks change in prodromal Huntington disease. Neuropsychology 2010;24(4):435–442. This is a most comprehensive study of timing impairments in HD. Cross-sectional and longitudinal effects sizes are excellent supporting usage of this test in clinical trials. PubMedCrossRef
39.
Jin X, Costa RM. Start/stop signals emerge in nigrostriatal circuits during sequence learning. Nature. 2010;466(7305):457–62.PubMedCrossRef
40.
•• Stout JC, Paulsen JS, Queller S, et al. Neurocognitive signs in prodromal huntington disease. Neuropsychology 2011;25(1):1–14. This is a most comprehensive summary of cross-sectional effect sizes in prodromal HD using a proximity index to estimate stage of HD prodrome. All new tests published should be compared against these effect sizes for inclusion in HD clinical trials. PubMedCrossRef
41.
Bechtel N, Scahill RI, Rosas HD, et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology. 2010;75(24):2150–60.PubMedCrossRef
42.
Johnson SA, Stout JC, Solomon AC, et al. Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington’s disease. Brain. 2007;130(Pt 7):1732–44.PubMedCrossRef
43.
Snowden JS, Austin NA, Sembi S, et al. Emotion recognition in Huntington’s disease and frontotemporal dementia. Neuropsychologia. 2008;46(11):2638–49.PubMedCrossRef
44.
Henley SMD, Wild EJ, Hobbs NZ, et al. Defective emotion recognition in early HD is neuropsychologically and anatomically generic. Neuropsychologia. 2008;46(8):2152–60.PubMedCrossRef
45.
de Gelder B, Van den Stock J, Balaguer RdD, Bachoud-Lévi A-C. Huntington’s disease impairs recognition of angry and instrumental body language. Neuropsychologia. 2008;46(1):369–73.PubMedCrossRef
46.
•• Calder AJ, Keane J, Young AW, et al. The relation between anger and different forms of disgust: Implications for emotion recognition impairments in Huntington's disease. Neuropsychologia 2010;48(9):2719–2729. This is a most comprehensive review of findings of emotional recognition in HD and an excellent study dissecting components of emotional recognition. PubMedCrossRef
47.
Hamilton JM, Murphy C, Paulsen JS. Odor detection, learning, and memory in Huntington’s disease. J Int Neuropsychol Soc. 1999;5(7):609–15.PubMedCrossRef
48.
Bacon Moore AS, Paulsen JS, Murphy C. A test of odor fluency in patients with Alzheimer’s and Huntington’s disease. J Clin Exp Neuropsychol. 1999;21(3):341–51.PubMedCrossRef
49.
Nordin S, Paulsen JS, Murphy C. Sensory- and memory-mediated olfactory dysfunction in Huntington’s disease. J Int Neuropsychol Soc. 1995;1(3):281–90.PubMedCrossRef
50.
Montoya A, Pelletier M, Menear M, et al. Episodic memory impairment in Huntington’s disease: a meta-analysis. Neuropsychologia. 2006;44(10):1984–94.PubMedCrossRef
51.
Solomon AC, Stout JC, Johnson SA, et al. Verbal episodic memory declines prior to diagnosis in Huntington’s disease. Neuropsychologia. 2007;45(8):1767–76.PubMedCrossRef
52.
Sadek JR, White DA, Taylor KI, et al. Retrograde amnesia in dementia: comparison of HIV-associated dementia, Alzheimer’s disease, and Huntington’s disease. Neuropsychology. 2004;18(4):692–9.PubMedCrossRef
53.
Paulsen JS, Butters N, Sadek JR, et al. Distinct cognitive profiles of cortical and subcortical dementia in advanced illness. Neurology. 1995;45(5):951–6.PubMed
54.
Paulsen JS, Butters N, Salmon DP, et al. Prism adaptation in Alzheimer’s and Huntington’s Disease. Neuropsychology. 1993;7(1):73–81.CrossRef
55.
Carella F, Bressanelli M, Piacentini S, et al. A study of arm movements in Huntington’s disease under visually controlled and blindfolded conditions. Neurol Sci. 2003;23(6):287–93.PubMedCrossRef
56.
Montoya A, Price BH, Menear M, Lepage M. Brain imaging and cognitive dysfunctions in Huntington’s disease. J Psychiatry Neurosci. 2006;31(1):21–9.PubMed
57.
Filoteo JV, Delis DC, Roman MJ, et al. Visual attention and perception in patients with Huntington’s disease: comparisons with other subcortical and cortical dementias. J Clin Exp Neuropsychol. 1995;17(5):654–67.PubMedCrossRef
58.
Nehl C, Ready RE, Hamilton J, Paulsen JS. Effects of depression on working memory in presymptomatic Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2001;13(3):342–6.PubMedCrossRef
59.
•• Thompson JC, Poliakoff E, Sollom AC, et al. Automaticity and attention in Huntington's disease: when two hands are not better than one. Neuropsychologia 2010;48(1):171–178. This is an excellent overview and dissection of attentional impairments in HD. PubMedCrossRef
60.
Smith MM, Long JD. Cognitive changes in prodromal Huntington Disease. Unpublished manuscript 2011, The University of Iowa Department of Psychiatry.
61.
Duff K, Beglinger LJ, Schultz SK, et al. Practice effects in the prediction of long-term cognitive outcome in three patient samples: a novel prognostic index. Arch Clin Neuropsychol. 2007;22(1):15–24.PubMedCrossRef
62.
Dutilh G, Krypotos AM, Wagenmakers EJ. Task-related versus stimulus-specific practice. Exp Psychol. 2011;1–9.
63.
Rosenblatt A, Kumar BV, Margolis RL, et al. Factors contributing to institutionalization in patients with Huntington’s disease. Mov Disord. 2011;Epub ahead of print. doi:10.​1002/​mds.​23716.
64.
•• O’Rourke JJ, Beglinger LJ, Smith MM, et al. The trail making test in prodromal Huntington disease: Contributions of disease progression to test performance. J Clin Exp Neuropsychol. 2011;33(5):567–579. This is a most comprehensive paper on the dissection of this common task and its utility in HD. PubMedCrossRef
65.
Paulsen JS, Salmon DP, Monsch AU, et al. Discrimination of cortical from subcortical dementias on the basis of memory and problem-solving tests. J Clin Psychol. 1995;51(1):48–58.PubMedCrossRef
66.
Beglinger LJ, Nopoulos PC, Jorge RE, et al. White matter volume and cognitive dysfunction in early Huntington’s disease. Cogn Behav Neurol. 2005;18(2):102–7.PubMedCrossRef
67.
Monsch AU, Bondi MW, Butters N, et al. A comparison of category and letter fluency in Alzheimer’s disease and Huntington’s disease. Neuropsychology. 1994;8(1):25–30.CrossRef
68.
Duff K, Paulsen JS, Beglinger LJ, et al. “Frontal” behaviors before the diagnosis of Huntington’s disease and their relationship to markers of disease progression: evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci. 2010;22(2):196–207.PubMedCrossRef
69.
Paulsen JS, Stout JC, DeLaPena JH, et al. Frontal behavioral syndromes in cortical and subcortical dementia. Assessment. 1996;3(3):327–37.CrossRef
70.
Paulsen JS, Stout JC, Tawfik-Reedy Z, et al. (editors). The utility of the Frontal Lobe Personality Scale (FLOPS) for characterizing behavior in dementia of the Alzheimer’s type (DAT) and Huntington’s disease (HD). Arch Clin Neuropsychol. 1996.
71.
Hartelius L, Jonsson M, Rickeberg A, Laakso K. Communication and Huntington’s disease: qualitative interviews and focus groups with persons with Huntington’s disease, family members, and carers. Int J Lang Commun Disord. 2010;45(3):381–93.PubMedCrossRef
72.
Rohrer D, Salmon DP, Wixted JT, Paulsen JS. The disparate effects of Alzheimer’s disease and Huntington’s disease on semantic memory. Neuropsychology. 1999;13(3):381–8.PubMedCrossRef
73.
Chenery HJ, Copland DA, Murdoch BE. Complex language functions and subcortical mechanisms: evidence from Huntington’s disease and patients with non-thalamic subcortical lesions. Int J Lang Commun Disord. 2002;37(4):459–74.PubMedCrossRef
74.
Saldert C, Fors A, Ströberg S, Hartelius L. Comprehension of complex discourse in different stages of Huntington’s disease. Int J Lang Commun Disord. 2010;45(6):656–69.PubMedCrossRef
75.
Ferm U, Sahlin A, Sundin L, Hartelius L. Using talking mats to support communication in persons with Huntington’s disease. Int J Lang Commun Disord. 2010;45(5):523–36.PubMedCrossRef
76.
Deckel AW, Morrison D. Evidence of a neurologically based “denial of illness” in patients with Huntington’s disease. Arch Clin Neuropsychol. 1996;11(4):295–302.PubMedCrossRef
77.
McGlynn SM. Behavioral approaches to neuropsychological rehabilitation. Psychol Bull. 1990;108(3):420–41.PubMedCrossRef
78.
Snowden JS, Craufurd D, Griffiths HL, Neary D. Awareness of involuntary movements in Huntington disease. Arch Neurol. 1998;55(6):801–5.PubMedCrossRef
79.
Vitale C, Pellecchia MT, Grossi D, et al. Unawareness of dyskinesias in Parkinson’s and Huntington’s diseases. Neurol Sci. 2001;22(1):105–6.PubMedCrossRef
80.
Ho AK, Robbins AO, Barker RA. Huntington’s disease patients have selective problems with insight. Mov Disord. 2006;21(3):385–9.PubMedCrossRef
81.
Hoth KF, Paulsen JS, Moser DJ, et al. Patients with Huntington’s disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol. 2007;29(4):365–76.PubMedCrossRef
82.
Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for disease progression in Huntington’s disease. Cochrane Database Syst Rev. 2009;(3):CD006455.
83.
Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008;5(2):181–97.PubMedCrossRef
84.
Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol. 2009;29(5):484–7.PubMedCrossRef
85.
Vaccarino AL, Anderson K, Borowsky B, et al. An item response analysis of the motor and behavioral subscales of the unified Huntington’s disease rating scale in huntington disease gene expansion carriers. Mov Disord. 2011;26(5):877–84.PubMedCrossRef
86.
87.
88.
89.
90.
Teixeira AL, Barbosa IG, Diniz BS, Kummer A. Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function. Biomarkers of Medicine. 2010;4(6):871–87.CrossRef
91.
Saleh N, Moutereau S, Azulay JP, et al. High insulinlike growth factor I is associate with cognitive decline in Huntington disease. Neurology. 2010;75(1):57–63.PubMedCrossRef
92.
Rowe KC, Paulsen JS, Langbehn DR, et al. Patterns of serotonergic antidepressant usage in prodromal Huntington disease. Psychiatry Res. 2011;In press.
Metadaten
Titel
Cognitive Impairment in Huntington Disease: Diagnosis and Treatment
verfasst von
Jane S. Paulsen
Publikationsdatum
01.10.2011
Verlag
Current Science Inc.
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 5/2011
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-011-0215-x

Weitere Artikel der Ausgabe 5/2011

Current Neurology and Neuroscience Reports 5/2011 Zur Ausgabe

ReviewPaper

Advances in Epigenetics and Epigenomics for Neurodegenerative Diseases

ReviewPaper

Fingolimod for Multiple Sclerosis: Mechanism of Action, Clinical Outcomes, and Future Directions

ReviewPaper

Role of Cerebrospinal Fluid and Plasma Biomarkers in the Diagnosis of Neurodegenerative Disorders and Mild Cognitive Impairment

ReviewPaper

The Radiologically Isolated Syndrome: Look (Again) Before You Treat

ReviewPaper

Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine

ReviewPaper

Gait Abnormalities in Multiple Sclerosis: Pathogenesis, Evaluation, and Advances in Treatment

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise